These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 30422669)

  • 1. Tumor-derived Autoantibodies Identify Malignant Pulmonary Nodules.
    Lastwika KJ; Kargl J; Zhang Y; Zhu X; Lo E; Shelley D; Ladd JJ; Wu W; Kinahan P; Pipavath SNJ; Randolph TW; Shipley M; Lampe PD; Houghton AM
    Am J Respir Crit Care Med; 2019 May; 199(10):1257-1266. PubMed ID: 30422669
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparative Study of Autoantibody Responses between Lung Adenocarcinoma and Benign Pulmonary Nodules.
    Wang J; Shivakumar S; Barker K; Tang Y; Wallstrom G; Park JG; Tsay JC; Pass HI; Rom WN; LaBaer J; Qiu J
    J Thorac Oncol; 2016 Mar; 11(3):334-45. PubMed ID: 26896032
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Significance of tumor-associated autoantibodies in the early diagnosis of lung cancer.
    Du Q; Yu R; Wang H; Yan D; Yuan Q; Ma Y; Slamon D; Hou D; Wang H; Wang Q
    Clin Respir J; 2018 Jun; 12(6):2020-2028. PubMed ID: 29356386
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autoantibody Signature Enhances the Positive Predictive Power of Computed Tomography and Nodule-Based Risk Models for Detection of Lung Cancer.
    Massion PP; Healey GF; Peek LJ; Fredericks L; Sewell HF; Murray A; Robertson JF
    J Thorac Oncol; 2017 Mar; 12(3):578-584. PubMed ID: 27615397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detecting pulmonary malignancy against benign nodules using noninvasive cell-free DNA fragmentomics assay.
    Xu S; Luo J; Tang W; Bao H; Wang J; Chang S; Zou Z; Fan X; Liu Y; Jiang C; Wu X
    ESMO Open; 2024 Aug; 9(8):103595. PubMed ID: 39088983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Gene Expression Classifier from Whole Blood Distinguishes Benign from Malignant Lung Nodules Detected by Low-Dose CT.
    Kossenkov AV; Qureshi R; Dawany NB; Wickramasinghe J; Liu Q; Majumdar RS; Chang C; Widura S; Kumar T; Horng WH; Konnisto E; Criner G; Tsay JJ; Pass H; Yendamuri S; Vachani A; Bauer T; Nam B; Rom WN; Showe MK; Showe LC
    Cancer Res; 2019 Jan; 79(1):263-273. PubMed ID: 30487137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A model based on the quantification of complement C4c, CYFRA 21-1 and CRP exhibits high specificity for the early diagnosis of lung cancer.
    Ajona D; Remirez A; Sainz C; Bertolo C; Gonzalez A; Varo N; Lozano MD; Zulueta JJ; Mesa-Guzman M; C Martin A; Perez-Palacios R; Perez-Gracia JL; Massion PP; Montuenga LM; Pio R
    Transl Res; 2021 Jul; 233():77-91. PubMed ID: 33618009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preoperative diagnosis of malignant pulmonary nodules in lung cancer screening with a radiomics nomogram.
    Liu A; Wang Z; Yang Y; Wang J; Dai X; Wang L; Lu Y; Xue F
    Cancer Commun (Lond); 2020 Jan; 40(1):16-24. PubMed ID: 32125097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum Protein Markers for the Early Detection of Lung Cancer: A Focus on Autoantibodies.
    Broodman I; Lindemans J; van Sten J; Bischoff R; Luider T
    J Proteome Res; 2017 Jan; 16(1):3-13. PubMed ID: 27769114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and validation of a plasma biomarker panel for discerning clinical significance of indeterminate pulmonary nodules.
    Daly S; Rinewalt D; Fhied C; Basu S; Mahon B; Liptay MJ; Hong E; Chmielewski G; Yoder MA; Shah PN; Edell ES; Maldonado F; Bungum AO; Borgia JA
    J Thorac Oncol; 2013 Jan; 8(1):31-6. PubMed ID: 23201823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Malignancy risk estimation of screen-detected nodules at baseline CT: comparison of the PanCan model, Lung-RADS and NCCN guidelines.
    van Riel SJ; Ciompi F; Jacobs C; Winkler Wille MM; Scholten ET; Naqibullah M; Lam S; Prokop M; Schaefer-Prokop C; van Ginneken B
    Eur Radiol; 2017 Oct; 27(10):4019-4029. PubMed ID: 28293773
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combining serum miRNAs, CEA, and CYFRA21-1 with imaging and clinical features to distinguish benign and malignant pulmonary nodules: a pilot study : Xianfeng Li et al.: Combining biomarker, imaging, and clinical features to distinguish pulmonary nodules.
    Li X; Zhang Q; Jin X; Cao L
    World J Surg Oncol; 2017 May; 15(1):107. PubMed ID: 28545454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Value of a Seven-Autoantibody Panel Combined with the Mayo Model in the Differential Diagnosis of Pulmonary Nodules.
    Ling Z; Chen J; Wen Z; Wei X; Su R; Tang Z; Hu Z
    Dis Markers; 2021; 2021():6677823. PubMed ID: 33688380
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Value of Combined Detection of Cytokines and Tumor Markers in the 
Differential Diagnosis of Benign and Malignant Solitary Pulmonary Nodules].
    Shi J; Liu X; Ming Z; Li W; Lv X; Yang X; Wang Y; Zhang M; Yang S
    Zhongguo Fei Ai Za Zhi; 2021 Jun; 24(6):426-433. PubMed ID: 34157802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of indeterminate pulmonary nodules detected in lung cancer screening: Diagnostic accuracy of FDG PET/CT.
    Garcia-Velloso MJ; Bastarrika G; de-Torres JP; Lozano MD; Sanchez-Salcedo P; Sancho L; Nuñez-Cordoba JM; Campo A; Alcaide AB; Torre W; Richter JA; Zulueta JJ
    Lung Cancer; 2016 Jul; 97():81-6. PubMed ID: 27237032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic strategy in patients with non-small cell lung cancer associated to satellite pulmonary nodules.
    Carretta A; Ciriaco P; Canneto B; Nicoletti R; Del Maschio A; Zannini P
    Eur J Cardiothorac Surg; 2002 Jun; 21(6):1100-4. PubMed ID: 12048092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Value of peripheral blood rare cell EGFR gene amplification detection in the evaluation of benign and malignant pulmonary nodules].
    Li H; Liu XQ; Yan LJ; Liu Y; Zhang JQ; Xiao YN; Li SQ
    Zhonghua Yi Xue Za Zhi; 2024 May; 104(18):1584-1589. PubMed ID: 38742345
    [No Abstract]   [Full Text] [Related]  

  • 18. Serological proteome analysis approach-based identification of ENO1 as a tumor-associated antigen and its autoantibody could enhance the sensitivity of CEA and CYFRA 21-1 in the detection of non-small cell lung cancer.
    Dai L; Qu Y; Li J; Wang X; Wang K; Wang P; Jiang BH; Zhang J
    Oncotarget; 2017 May; 8(22):36664-36673. PubMed ID: 28456790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A prediction model based on DNA methylation biomarkers and radiological characteristics for identifying malignant from benign pulmonary nodules.
    Xing W; Sun H; Yan C; Zhao C; Wang D; Li M; Ma J
    BMC Cancer; 2021 Mar; 21(1):263. PubMed ID: 33691657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and external validation of a multimodal integrated feature neural network (MIFNN) for the diagnosis of malignancy in small pulmonary nodules (≤10 mm).
    Yang R; Zhang Y; Li W; Li Q; Liu X; Zhang F; Liang Z; Huang J; Li X; Tao L; Guo X
    Biomed Phys Eng Express; 2024 May; 10(4):. PubMed ID: 38684143
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.